ARMINE GUKASYAN: Open Payments
NPI 1881280295 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$857 in 29 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $131 · 2025 $857
Food & beverage: $857
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $357 |
| GENZYME CORPORATION | 5 | $160 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $74 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| CSL Behring | 2 | $51 |
| Optinose US, Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
Products named: DUPIXENT, NEFFY, Xhance, Rhapsido, Haegarda, NUCALA, DAWNZERA, BREZTRI.
Industry payments across CA — which companies pay providers there.
